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Type B adverse drug reactions can affect any organ, but the 
most common organs involved are liver, skin, and bone mar-
row. The life-threatening type B adverse drug reactions noted 
for drugs include hepatotoxicity,2 severe cutaneous reactions,3-5 
aplastic anaemia6 and blood dyscrasias.7 Amongst these, hepato-
toxicity is the most frequent reason for drug withdrawal and is 
also the major cause of attrition in drug discovery/development.8 
Manifestations of liver injury can range from mild, asymptom-
atic changes in serum transaminases, which occur at high fre-
quency with a number of drugs, to fulminant liver failure, which, 
although rare, can be potentially life-threatening and may neces-
sitate a liver transplant. Considering that the liver is exposed to 
high concentrations of drug/metabolite(s) after oral administra-
tion, it is not altogether surprising that the organ is particularly 
vulnerable to damage by xenobiotics including drugs. The role 
of drug metabolism and reactive metabolites that cause these 
serious reactions have been investigated over the past 25 years 
and will be the focus of this review. Clinical management is still 
empirical, but recognition of a drug induced disease is important 
for future management of the patient.
Reactive Metabolites
The basic principle of drug metabolism is to convert a lipophilic 
drug or xenobiotic to hydrophilic metabolites that can be more 
readily excreted from the body. Sometimes during this process of 
biotransformation some of the drug or xenobiotic may be acti-
vated to chemically reactive species, i.e. reactive metabolites. This 
biotransformation of relatively inert chemicals to highly reactive 
intermediary metabolites is commonly referred to as metabolic 
activation or bioactivation, and it is known to be the initial event 
in many chemically induced toxicities. Some toxicants are direct 
acting and require no activation, whereas other chemicals may be 
activated nonenzymatically.9 The focus of this review, however,   
is on xenobiotics requiring metabolic activation and to those   
processes involved in activation.
In the 1940s and 1950s the pioneering studies of James and 
Elizabeth Miller provided early evidence for in vivo conversion 
of chemical carcinogens to reactive metabolites. They found 
that reactive metabolites of the aminoazo dye N,N-dimethyl-
4-aminoazobenzene (DAB), a hepatocarcinogen in rats, would 
bind covalently to proteins and nucleic acids. The term, meta-
bolic activation, was coined by the Millers to describe this pro-
cess. Moreover they demonstrated that covalent binding of these 
chemicals was an essential part of the carcinogenic process.10 The 
overall scheme of metabolism for potentially toxic xenobiotics is 
outlined in Figure 1. As illustrated by this diagram, xenobiotic 
Introduction
The World Health Organization defines adverse drug reactions 
as “a response to a drug that is noxious, unintended and occurs 
at doses normally used in man for the prophylaxis, diagnosis, 
or therapy of disease or for modification of the physiological 
function.” Adverse drug reactions can be generally classified into 
type-A and type B reactions. Type-A reactions are associated 
with the primary pharmacology of the drug (e.g., risk of hypo-
tension with antihypertensives) and are responsible for 80% of 
all side effects. Type-A adverse drug reactions can be detected in 
animal models of pharmacology and/or toxicology; they exhibit 
simple dose-response relationships and are usually avoided in the 
clinic via dose adjustments. In contrast, type-B (bizarre or idio-
syncratic) adverse drug reactions are unrelated to known drug 
pharmacology, and although they are dose dependent in suscep-
tible individuals, they do not occur at any dose in most patients. 
Because the frequency of occurrence of idiosyncratic adverse 
drug reactions is very low these reactions are often not detected, 
until the drug has gained broad exposure in a large patient popu-
lation. Importantly, standard regulatory animal toxicity studies 
have traditionally shown a poor concordance with occurrence of 
idiosyncratic adverse drug reactions in humans.1 
*Correspondence to: Sabry M. Attia; Email: attiasm@ksu.edu.sa
Submitted: 06/28/10; Revised: 08/03/10; Accepted: 08/04/10
Previously published online:
www.landesbioscience.com/journals/oximed/article/13246
DOI: 10.4161/oxim.3.4.13246
A number of drugs have been withdrawn from the market 
or severely restricted in their use because of unexpected 
toxicities that become apparent only after the launch of 
new drug entities. Circumstantial evidence suggests that, 
in most cases, reactive metabolites are responsible for these 
unexpected toxicities. in this review, a general overview of the 
types of reactive metabolites and the consequences of their 
formation are presented. The current approaches to evaluate 
bioactivation potential of new compounds with particular 
emphasis on the advantages and limitation of these procedures 
will be discussed. reasonable reasons for the excellent safety 
record of certain drugs susceptible to bioactivation will also 
be explored and should provide valuable guidance in the use 
of reactive-metabolite assessments when nominating drug 
candidates for development. This will, in turn, help us to design 
and bring safer drugs to the market. 
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metabolism can produce not only nontoxic metabolites, which 
are more polar and readily excreted (detoxication), but also 
highly reactive metabolites, which can interact with vital intra-
cellular macromolecules, resulting in toxicity. In addition reac-
tive metabolites can be detoxified for example, by interaction 
with glutathione (GSH).
Within the tissue a variety of reactions may occur depend-
ing on the nature of the reactive species and the physiology of 
the organism. Reactive metabolites are usually electron deficient 
molecules and are referred to as electrophiles (molecules contain-
ing positive centers). If not detoxified properly, these electrophiles 
can react with electron rich species, i.e. nucleophiles (molecules 
containing negative centers), through covalent bond formation. 
The nucleophiles usually contain atoms such as S, N, or O that 
have a lone pair of electrons, which can form a new bond to the 
electrophile. Such nucleophiles are present on macromolecules 
such as proteins, nucleic acids and lipids. Chemically reactive 
metabolites can directly react with proteins causing changes in 
protein structure or protein folding.11,12 These modified proteins 
are processed by antigen presenting cells and can look “foreign” to 
the immune system leading to an immune response. Chemically 
reactive electrophiles can also covalently react with nucleic acids 
on the DNA thereby causing changes in DNA structure or gene 
expression. Changes in DNA can lead to mutagenicity, teratoge-
nicity or carcinogenicity.13-16
Types of reactive metabolites. Reactive metabolites include 
such diverse groups as epoxides, quinones, free radicals, reactive 
oxygen species, and unstable conjugates. As a result of their high 
reactivity, reactive metabolites are often considered to be short-
lived. This is not always true, however, because reactive interme-
diates can be transported from one tissue to another, where they 
may exert their deleterious effects.9 For example, carcinogenic aro-
matic amines are metabolized in the liver to the N-hydroxylated 
derivatives that, following sulfation and/or acetylation conjuga-
tion, are transported to the bladder, where the N-hydroxy deriva-
tive is released under the acidic conditions of urine.16
As mentioned above, reactive metabolites are usually electro-
philes or free radicals. Electrophiles can be further subdivided 
into hard or soft depending on how concentrated or diffuse 
their electron deficient site is. Soft electrophiles are generally 
uncharged and are less electrophilic. Example of soft electro-
philes are Michael acceptor, quinine methide and iminoquinone. 
Hard electrophiles are generally small and charged such as alkyl 
carbocation, carbonyl carbocation and nitrenium ion.17 Soft elec-
trophiles react with soft nucleophiles through orbital interac-
tions, while hard electrophiles react with hard nucleophiles to a 
large degree through electrostatic interactions. Examples of soft 
nucleophiles are RSH, GSH, RS-, I-, RSe-, alkenes and R3P (soft 
because the nucleophilic site is a sulfur atom, which is relatively 
large and hence its electron cloud is more polarizable). In con-
trast, R-NH2, R-OH, RO-, SO4
2-and Cl- are hard nucleophiles 
because nitrogen is small and much less polarizable relative to 
sulfur. Several factors play a role in the formation and reactivity 
of theses reactive metabolites. These factors include the presence 
of a good leaving group (such as sulfate, sulfonate, chloride, and 
acetate), ring strain, polarization of a double bound by a carbonyl 
group (Michael acceptor), and the presence of electron withdraw-
ing groups.11
Free radicals are another kind of reactive metabolite that can 
be formed by xenobiotics.18 Free radical refers to compounds hav-
ing an unpaired electron. Since electrons “like” to be paired to 
form a chemical bond, a free radical cannot react covalently with 
nucleophiles. Rather they react with another free radical to form 
a covalent bond, abstract a hydrogen atom from a neutral mol-
ecule to generate a new radical, or abstract an electron to form an 
anion and generate a radical cation. An example of a free radical 
mechanism is the ring opening of cyclopropyl ring of tertiary 
amine as in trovofloxacin (Fig. 2). It has been reported that 
trovafloxacin-induced hepatotoxicity may be mediated through 
the oxidation of the cyclopropylamine substructure to reactive 
intermediates that may form covalent adducts to hepatic proteins, 
resulting in damage to liver tissue.19
Free radicals can occur, for example, in lipids, amino acids, 
nucleotides, and oxygen compounds. Oxygen radicals are of par-
ticular importance as they can trigger the formation of all other 
radicals. Other oxygen containing species that are chemically 
not radicals also have high reactivity with biological substances. 
Jointly, these substances are known as reactive oxygen species 
(ROS) (Fig. 3). In addition to ROS, there are radicals that con-
tain an additional nitrogen atom for example, nitric oxide (NO). 
NO can be generated enzymatically by the so-called NO syn-
thases (NOS) or non-enzymatically by nitrite (NO2-). NO has 
important signalling and protective functions; in 1998, a Nobel 
Prize was awarded for their discovery. NO/NO2- and ROS, in 
turn, can react with each other. This generates peroxynitrite 
(ONOO-), the most reactive compound of all ROS, which can 
oxidize and nitrite proteins, lipids, and nucleic acids.20
It is worthwhile to note that free radicals are a two-edged 
sword. On the one hand, they have important physiological func-
tions. In addition to NO, which is an important protective factor 
in the vasculature and a neurotransmitter in the nervous system,21 
oxygen radicals are, for example, essential in the immune defence, 
as well as in the regulation of cellular growth and gene expres-
sion.22 But too much of a good thing can literally be harmful, 
Figure 1. The relationship between metabolism, activation, detoxica-
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because radicals are also highly dangerous by-products of the cel-
lular metabolism.23 An oxidative imbalance, i.e., a disturbance in 
the balance between the production of ROS (especially free radi-
cals) and antioxidant defenses, has been described as an oxidative 
stress status.24 This can result in several kinds of cell damage, 
leading to a loss of function and integrity. Undesirable effects 
include inactivation of NO as a result of a direct chemical reac-
tion with ROS and oxidative damage of cell components such as 
DNA and proteins.20,25 These effects are potentially involved in 
the development of a large number of pathological conditions,26,27 
including cardiovascular diseases, neurological disorders, cancer 
and aging process.28-33
Reactivity and toxicity of reactive metabolites. The rela-
tionship between drug metabolism and adverse drug reactions 
was first demonstrated with the analgesic agent paracetamol. 
Paracetamol is a major cause of drug-related morbidity and mor-
tality in humans, capable of producing hepatic necrosis after a 
single toxic overdose.34 At normal therapeutic doses, paracetamol 
is safe, but can be hepatotoxic at high doses. The major portion of 
paracetamol is conjugated with either sulfate or glucuronic acid 
to form water-soluble, readily excreted metabolites and only small 
amounts of the reactive intermediate, believed to be N-acetyl-
p-benzoquinonimine (NAPQI), are formed by the cytochrome 
P450 enzymes (Figure 4). When therapeutic doses of paracetamol 
are ingested, the small amount of reactive intermediate forms is 
efficiently deactivated by conjugation with GSH. When large 
doses are ingested, however, the sulfate and glucuronide cofactors 
(PAPS and UDPGA) become depleted, resulting in more of the 
paracetamol being metabolized to the reactive intermediate.35-37 
As long as GSH is available, most of the reactive intermediate 
can be detoxified. When the concentration of GSH in the liver 
also becomes depleted, however, covalent binding to sulfhydryl 
(-SH) groups of various cellular proteins increases, resulting in 
Figure 2. Free radical mechanism of cyclopropylamine ring opening: insights into trovafloxacin-induced hepatotoxicity.
Figure 3. reactive oxygen species (rOS). O2- superoxide radical, H2O2 
= hydrogen peroxide, SOD = superoxide dismutase, Cat = catalase, NO 
= nitric oxide, NO2-nitrite, ONOO- = peroxynitrite, Nitrated proteins 
are biomarkers for oxidative stress. red indicates disease promoting 
proteins or compounds; green, protective factors; arrows, reactions or 
transformations; a box indicates a protein for example, an enzyme or 
receptor. The processes shown within the grey area occur naturally in 
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hepatic necrosis. If sufficiently large amounts of paracetamol are 
ingested, as in drug overdoses and suicide attempts, extensive 
liver damage and death may result.
Following the studies with paracetamol, there have been 
myriad examples of drugs associated with idiosyncratic adverse 
drug reactions for which reactive-metabolite formation has been 
demonstrated.38 These examples provide a circumstantial link 
between reactive-metabolite formation and toxicity. It is very 
important to make a distinction here between drugs that exhibit 
dose-dependent and dose-independent adverse drug reactions. 
The hepatotoxic effects of paracetamol in humans can hardly be 
considered as idiosyncratic as they are dose dependent and can be 
replicated in animals.35-37 In contrast, drugs like the antidiabetic 
agent troglitazone, which exhibits dose-independent hepatotoxic-
ity in a very small segment of the population, is a true example of 
an idiosyncratic toxin, given that this compound received a ‘clean 
bill of health’ in conventional animal toxicological assessments.
In certain cases the metabolites are so reactive that they do not 
escape the enzyme that formed them and covalently bind to the 
enzyme leading to irreversible inhibition.39,40 Because metabolism 
precludes enzyme inactivation, these compounds fall into the cat-
egory of mechanism-based inactivators. Inactivation can occur 
via coordination of the reactive species with the heme prosthetic 
group (formation of a metabolite-inhibitor (MI) complex) or via 
covalent adduction of the reactive intermediate with heme and/or 
with an amino acid residue on the apoprotein. Cytochrome P450 
inactivation can translate into clinical drug-drug interactions, 
some of which can be potentially deleterious, and can lead to 
the withdrawal of the perpetrator drug. For instance, co-admin-
istration of the calcium-channel blocker and potent P450-3A4 
inactivator mibefradil and simvastatin in patients with hyperten-
sion has been associated with increased cases of myopathy includ-
ing rhabdomyolysis. The biochemical mechanism for the clinical 
drug-drug interactions involves the 
mechanism-based inactivation of 
the P450-3A4-catalyzed simvastatin 
metabolism process by mibefradil; 
a consequence which results in ele-
vated plasma concentrations of the 
statin.41,42 Myopathy or rhabdomy-
olysis is a rare side effect common 
to the statin class of compounds and 
is usually associated with high levels 
of HMG-CoA reductase inhibitory 
activity in susceptible target tissue. 
Given the potential for such life-
threatening drug-drug interactions, 
the manufacturer of mibefradil 
announced a voluntary withdrawal of 
the drug from the market worldwide.
Dietary supplements containing 
Piper methysticum (kava) have been 
implicated in multiple cases of liver 
injury in humans following the usage 
of kava-containing products. Its seda-
tives and anxiolytic benefits have been 
hampered by several reports of clinically significant herb-drug inter-
actions upon concomitant use with benzodiazepines and barbitu-
rates,43,44 and several cases of idiosyncratic hepatotoxicity have also 
been reported.45 Consequently, over-the-counter sales of kava herbal 
preparations have been banned in several countries in the European 
Union. Studies on P450 inhibition with kavalactone derivatives 
methysticin and 7,8-dihydromethysticin (Fig. 5), the major con-
stituents of kava extract,46 have revealed potent mechanism-based 
inactivation of multiple human P450 enzymes.47 The time- and 
NADPH-dependent formation of the 455-nm absorbing MI com-
plex is consistent with a bioactivation mechanism involving the 
metabolism of the 1,3-benzodioxole group to the corresponding car-
bene intermediate followed by its coordination with the heme iron.47
Consistent with this finding, the kavalactone kawain (Fig. 5), 
which differs from methysticin in that it does not contain the 
1,3-benzodioxole group is not a P450 inactivator.47 GSH conju-
gates of electrophilic ortho-quinone intermediates obtained via the 
biotransformation sequence (1,3-benzodioxole→catechol→ortho-
quinone) in methysticin and 7,8-dihydromethysticin have also 
been identified in rat and human liver microsomes (Fig. 5), and the 
involvement of these reactive quinonoid intermediates in the immu-
noallergic hepatotoxic effects of kava extract has been speculated.48 
Overall, given the potential for drug-drug interactions via enzyme 
inactivation, mechanism-based inactivation of major human P450 
enzymes by new compounds is routinely assessed in a drug- 
discovery paradigm.
Reactive metabolites which covalently bind to the DNA have 
a dominant role in the mutagenicity and carcinogenicity. The 
concept of genotoxic/mutagenic response arising from metabo-
lism was first proposed in the 1930s and the 1940s to account 
for the carcinogenicity of chemically inert polycyclic aromatic 
hydrocarbons, aminoazo dyes, and nitroso compounds.49,50 All 
pharmaceutical companies utilize a standard battery of genetic 
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toxicology assays to test the muta-
genic potential of drug candidates.51 
These assays measure several dif-
ferent types of genetic damage in a 
variety of cell types to increase the 
probability of detecting a mutagenic 
response. The endpoints routinely 
monitored include the induction of 
gene mutations and chromosomal 
aberrations in bacteria and mamma-
lian cells, respectively, as well as the 
production of DNA strand breaks, 
DNA intercalation, and covalent 
modification.
An ariclor-1254-induced rat 
liver S-9/NADPH system has been 
adopted in these in vitro tests for 
detecting pro-mutagens capable 
of forming DNA-reactive metabo-
lites.52 Genetic toxicology assess-
ments have become an integral part 
of drug safety evaluation and are 
required by regulatory agencies for 
drug approvals worldwide. Because 
a good correlation has been estab-
lished between in vitro metabolism 
dependent mutagenic response and 
the outcome of rodent carcinoge-
nicity evaluations, drug candidates 
intended for non-life-threatening indications are generally dis-
continued from development, when they exhibit a positive 
response in the in vitro assays in the presence of S-9/NADPH. 
An example of this phenomenon was highlighted with a study on 
the anti-obesity agent and 5-hydroxytryptamine (5-HT)2C ago-
nist 2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine (1; Figure 
6).40 The attractive in vitro/in vivo pharmacology and pharmaco-
kinetic attributes of 1 were offset by its S-9/NADPH-dependent 
genotoxic effects in the bacterial Salmonella Ames assay, which 
led to its discontinuation from clinical development. Studies with 
(14C)-1 revealed the irreversible and concentration-dependent 
incorporation of radioactivity in calf thymus DNA in an S-9/
NADPH-dependent fashion confirming that 1 was bioactivated 
to a DNA-reactive metabolite.
Reactive-metabolite trapping studies in S-9/NADPH incuba-
tions containing exogenously added hard and soft nucleophilic 
trapping agents methoxylamine and GSH, respectively, led to 
the detection of conjugates of 1 and its downstream metabolites. 
Structural elucidation of these conjugates by mass spectrometry 
allowed an insight into the bioactivation pathways leading to the 
formation of DNA-reactive metabolites. The mass spectrum of the 
methoxylamine conjugate of 1 was consistent with condensation 
of amine with an electrophilic, aldehyde metabolite derived from 
piperazine ring scission in 1 (Fig. 6, Pathway a), whereas, the mass 
spectrum of the GSH conjugate suggested a bioactivation pathway 
involving initial aromatic ring hydroxylation on the 3-chlorobenzyl 
motif in 1, followed by β-elimination to a quinone-methide species 
that reacted with GSH (Fig. 6, Pathway b). The observation   
that methoxylamine and GSH reduced mutagenicity suggested 
that the trapping agents competed with DNA towards reaction 
with the reactive metabolites.
Perhaps the most important susceptibility factor for type-B 
adverse drug reactions is genetic variability. Genetic polymor-
phisms have a strong influence on drug metabolism and may 
increase risk of toxicity. For example, polymorphism of the 
N-acetyltransferase (NAT) 2 gene differentiates fast from slow 
acetylators; the latter have increased susceptibility to toxic-
ity of certain aniline-containing drugs such as isoniazid, sulfa-
methoxazole, dapsone, and procainamide.53,54 The major route 
of elimination of these drugs in humans involves N-acetylation 
of the aniline moiety by NAT2, resulting in the neutral amide 
metabolites. In a NAT2-deficient population, the aniline motif 
in isoniazid is hydrolyzed by amidases liberating hydrazine, 
which is toxic in its own right; likewise, sulfamethoxazole, dap-
sone, and procainamide are biotransformed by P450 enzymes 
to yield cytotoxic and protein-reactive metabolites that include 
N-hydroxyaniline derivatives and the subsequent two-electron 
oxidation products, i.e., the nitroso intermediates. The reactivity 
of the nitroso metabolites of these drugs with GSH and/or pro-
teins in target organs has also been demonstrated.55,56
Genetic polymorphisms in glutathione-S-transferase (GST) 
isozymes, which catalyze GSH conjugation to reactive metabo-
lites, are also considered risk factors for hepatotoxicity caused 
by several drugs such as troglitazone and carbamazepine.57,85   
Figure 5. Proposed mechanisms of P450 inactivation and hepatotoxicity by components of kava 
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It is possible that patients deficient in GST isozymes are most at 
risk towards liver injury by reactive metabolites of troglitazone 
and carbamazepine because of ineffective scavenging of the 
reactive metabolites derived from the oxidative bioactivation of 
these drugs. There is also a strong possibility that components of 
ingested foods including herbal supplements can modulate drug 
metabolism and, therefore, increase idiosyncratic adverse drug 
reaction risk. For example, chronic alcohol abuse increases the 
risk of paracetamol hepatotoxicity by inducing P450-2E1, which 
predominantly catalyzes paracetamol bioactivation to NAPQI.59
Individual group summaries. Most reactive metabolites 
are formed by phase-I metabolic pathways; however, some-
times phase-II pathways can also generate reactive metabolites. 
Usually phase-II metabolism, such as the conjugation reactions 
(glucuronidation and sulfation), increases the polarity of a drug 
making it more polar and readily excreted from the body. In rare 
cases, these conjugates can be chemically reactive leading to tox-
icity. In the following section some reactive metabolites of drugs 
or xenobiotics are discussed with respect to their reactivity and 
deleterious effects. Elucidation of bioactivation pathways pro-
vides valuable information that can lead to designing safer drug 
candidates.
Quinones. Quinones represent one of the most frequently 
generated reactive intermediates. Quinones are known to cause 
a variety of toxicological effects in vivo including acute cyto-
toxicity, immunotoxicity, genotoxicity and carcinogenesis.60-63 
Quinones can be viewed as Michael acceptors and can cause 
cellular damage through alkylation of crucial cellular proteins 
and/or DNA. Quinones are also highly redox active molecules, 
which can redox cycle with their semiquinone radicals leading to 
formation of ROS including super-
oxide, hydrogen peroxide, and 
ultimately the hydroxyl radical. 
Production of ROS can cause severe 
oxidative stress within cells through 
the formation of oxidized cellular 
macromolecules, including lipids, 
proteins, and DNA (Fig. 7).
Benzene, a common solvent used 
in organic chemistry, is converted to 
hydroquinone by liver P450, and the 
subsequent peroxidase-catalyzed oxi-
dation of this metabolite to p-ben-
zoquinone in the bone marrow may 
explain the induction of leukaemia 
during chronic exposure to this sol-
vent. The fact that p-benzoquinone 
is known to form DNA adducts 
strengthens this hypothesis.64 It has 
been demonstrated that inhibition 
of human topoisomerases I and II 
by high concentrations of quinoid 
metabolites of benzene; however, a 
remarkably greater sensitivity of the 
enzymes was detected with phenolic 
metabolites of benzene in the course 
of their bioactivation using a peroxidase/H2O2 system. This 
suggests that free radical intermediates of phenolic oxidation 
(formed in the presence of peroxidase activity) may contribute to 
the clastogenic and carcinogenic effects of phenolic compounds 
through inhibition of topoisomerases.65
Etoposide has become one of the most widely used anticancer 
drugs in the world since its introduction.66 However, etoposide 
is a somatic and germ-cell mutagen capable of inducing both 
numerical and structural chromosome aberrations in animals.67-70 
Moreover, numerous groups have reported that treatment sched-
ules associated with the impressive efficacy of etoposide are also 
associated with an increased risk of secondary acute myeloid leu-
kaemia.71-73 This has prompted the removal of this highly effec-
tive anti-topoisomerases II agent from some treatment regimens. 
It is believed that the mechanisms for the extremely high suscep-
tibility of myeloid stem cells to the leukemogenic effects of etopo-
side is due to etoposide phenoxyl radicals (etoposide-O•) formed 
from etoposide by myeloperoxidase.74,75 Etoposide-O• is reduced 
back to etoposide via oxidation of intracellular thiols (RSH), i.e., 
glutathione and sulfhydryl groups of proteins. Reduced etoposide 
is thus repeatedly available as a substrate for myeloperoxidase, 
at the expense of intracellular thiols, which undergo one elec-
tron oxidation to reactive thiyl radicals (RS•). RS• can further 
react to generate disulfide anion-radicals (RS-S-•R), which can 
donate an electron to oxygen. Superoxide anion radical (O2-•) 
thus produced can form, in the presence of transition metal 
complexes, the extremely reactive hydroxyl radical (HO•). It is 
believed that accumulation of these radicals may cause damage 
to cell membrane leading to lipid peroxidation and also dam-
age to cellular genome and other critical biomolecules, ultimately 
Figure 6. Postulated bioactivation pathways which explain the mutagenicity of the anti-obesity agent 
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inducing mutageneicity and leu-
kaemia (Fig. 8).13-16,76,77 It is worth-
while to note that several strategies 
have been developed to decrease the 
deleterious effects of etoposide in 
normal cells using nutritional anti-
oxidants such as vitamin C, vitamin 
E homolog,74,76 and the metal-chela-
tor, dexrazoxane.78 Ameliorations of 
these deleterious effects were associ-
ated with a concomitant alteration of 
the antioxidant potential.
Remoxipride is an atypical anti-
psychotic used in the treatment of 
schizophrenia. It is associated with 
rare cases of aplastic anaemia. It has 
been demonstrated that the metabo-
lite of remoxipride, NCQ344, forms 
a reactive p-quinone,79 which might 
be responsible for the aplastic anae-
mia associated with remoxipride 
(Fig. 9).
Iminoquinones. Iminoquinones 
are another class of reactive metabo-
lites formed by the substitution of 
one of the oxygen atoms of the qui-
none with nitrogen; they can also 
act as Michael acceptors. Because nitrogen is less electronegative 
than oxygen, the reactivity of an iminoquinone will be relatively 
lower compared to a quinone. Once generated, an iminoquinone 
can covalently bind to protein nucleophiles and cause toxicity. 
A number of drugs and chemicals of environmental importance 
can be converted to reactive quinonimines. The 4-aminoquino-
line antimalarial, amodiaquine, was withdrawn from the mar-
ket because of idiosyncratic agranulocytosis and hepatotoxicity, 
and this was attributed to its bioactivation to a quinonimine 
metabolite.80 Iminoquinones preferentially react with thiol 
nucleophiles. In the case of the drug, acetaminophen, the reactive 
intermediate NAPQI, once formed, interacts with protein thiols, 
including that of the plasma membrane Ca2+-ATPase, causing 
increased cytosolic calcium concentrations, adverse cytoskeletal 
effects, and cell death.81 Lumaricoxib is a new COX-2 inhibitor 
used for the treatment of inflammatory diseases. It is associated 
with idiosyncratic hepatotoxicity in patients. It has been dem-
onstrated that lumaricoxib is bioactivated to a reactive quinone 
(Fig. 10), which might be responsible for causing idiosyncratic 
hepatotoxicity.82
Quinonemethide. Quinonemethide is a class of reactive 
metabolite in which one of the oxygens of a quinone is substi-
tuted by carbon. Because of this, the double bond is polarized 
and can react in a Michael fashion with nucleophiles. The reac-
tivity of the quinone methide depends on the other substituents. 
A series of o-methoxy-4-alkylphenols were used to investigate 
the electrophilicity and toxicity of quinonemethide intermedi-
ates.83 It was observed that the reactivity of the corresponding 
quinone methide was influenced by the presence and nature of 
substituents on the benzylic carbon; increased steric hindrance 
of the exocyclic methylene group decreased the rate of nucleo-
philic attack.
Moreover, the quinine methides formed from o-methoxy-
4-alkylphenols of intermediate reactivity were the most cyto-
toxic, presumably because quinone methides that do not exhibit 
this optimum reactivity are either too stable to react with critical 
cellular nucleophiles or so reactive with solvent so as to preclude 
reaction with critical cellular nucleophiles.83 Acolbifene is a selec-
tive estrogen receptor modulator developed for the treatment of 
breast cancer. It has been demonstrated that acolbifene can be 
bioactivated to electrophilic quinonemethide and diquinoneme-
thide reactive intermediates,84 which could cause further toxicity 
(Fig. 11). It has also been shown that these reactive metabolites 
bind with the deoxynucleosides causing DNA damage.
Arene oxides and epoxides. Arene oxides are another class of 
reactive intermediates formed by numerous drugs that are asso-
ciated with idiosyncratic drug reactions. Cytochrome P450 
enzymes are capable of catalyzing this biotransformation in aro-
matic compounds. In the case of alkenes, the corresponding epox-
ides are formed. Both arene oxides and epoxides are reactive and 
are capable of reacting with nucleophilic proteins.85 The major 
in vivo detoxification pathways for these arene oxides involve 
enzymes such as epoxide hydrolase and glutathione-S-transferase. 
An example of an epoxide is a metabolite of the drug carbamaze-
pine. Carbamazepine is an anticonvulsant drug associated with a 
variety of idiosyncratic drug reactions such as skin rashes, aplas-
tic anaemia, hepatitis, and generalized anticonvulsant hypersen-
sitivity syndrome. Carbamazepine is biotransformed to a weakly 
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reactive 10, 11-epoxide by P450-3A4/P450-2C8 (Fig. 12). 
This is deactivated by epoxide hydrolase to dihydrodiols.86
Zomepirac is an anti-inflammatory drug (NSAID), which is 
associated with severe and fatal anaphylactic reactions because 
of which it was withdrawn from the market in 1983. It has been 
shown that zomepirac is bioactivated to arene oxide reactive 
intermediates, which could possibly cause these adverse reactions 
(Fig. 13).87
Glucuronidation. Glucuronidation is a process by which a 
drug or other substrate, which usually contain OH groups i.e., 
phenols, carboxylic acids, and alcohols, are cleared and detoxi-
fied. In the case of diclofenac, the carboxylic acid is converted 
to a glucuronide. This glucuronide is 
reactive and slowly reacts with pro-
tein amino groups leading to cova-
lent binding.88,89 In some cases, the 
acyl glucuronide also undergoes ring 
opening and an Amadori rearrange-
ment that can lead to the forma-
tion of irreversible protein binding 
(Fig. 14). Carboxylic acids can also 
form Co-A esters, which are reactive 
because the Co-A group is a good 
leaving group. These esters may also 
contribute significantly to the cova-
lent binding associated with carbox-
ylic acids.90
Sulfation. Sulfation is another 
phase-II pathway in which the SO3- 
functional group is transferred to the 
substrate through a sulfotransferase 
enzyme. The usual substrates for this 
type of reaction are hydroxyl or phe-
nolic groups. Substrates containing 
nitrogen may also undergo this bio-
transformation. Usually these sulfate 
conjugates are nontoxic and can be 
excreted from the body. But in some 
cases, the sulfate group in the conju-
gate is reactive and can be displaced 
by a nucleophile or act as a leaving 
group to form a cation,91 that can 
covalently bind to a protein leading 
to toxicity. An example is the bioac-
tivation of an antifungal compound 
called N-(3,5-dichlorophenyl) suc-
cinimide (NDPS), which is known 
to cause nephrotoxicity. It was 
shown that its hydroxyl metabo-
lite N-(3,5-dichlorophenyl)-2-
hydroxysuccinimide (NDHS) is 
bioactivated to an activated O-sulfate 
that is likely responsible for the toxic-
ity (Fig. 15).92
Detection and screening for reac-
tive metabolites. Given the lack of 
availability of preclinical models as reliable predictors of idiosyn-
cratic adverse drug reactions and the absence of relevant clinical 
safety biomarkers, it is currently impossible to accurately predict 
which new drugs will be associated with a significant incidence of 
idiosyncratic adverse drug reactions. Under the assumption that 
reactive metabolites, as opposed to the parent molecules from 
which they are derived, can be responsible for the pathogenesis 
of certain toxicities, most pharmaceutical companies have imple-
mented assays to evaluate a compound’s potential to undergo 
bioactivation with the goal of eliminating or minimizing reac-
tive-metabolite formation by rational structural modification of 
the problematic chemical series.
Figure 9. Bioactivation of the remoxipride metabolite, NCQ344, to a reactive p-quinone.
Figure 8. Potential cyto- and genotoxic pathways triggered by myeloperoxidase- catalyzed generation 
of etoposide phenoxyl radicals. vP = etoposide, Ph = phenoxyl radicals, sQ = semi-quinone free radical, 
CA = chromosomal aberration, LP = lipid peroxidation, rSH = intracellular thiols, rS• = thiyl radicals, rS-
S-•r = disulfide anion-radicals, HO• = hydroxyl radical.246  Oxidative Medicine and Cellular Longevity  volume 3 issue 4
Avoiding structural alerts. 
The initial step to avoid the 
formation of reactive metabo-
lites is to identify functional 
groups that are known to form 
reactive metabolites and avoid 
these functional groups in the 
structure of drug candidates. 
For example, functional groups 
such as aromatic amines are 
known to form reactive nitroso 
species.93 Another example is 
the hydrazine functional group 
that can form reactive carboca-
tion species.94 A good review 
of structural alerts is found in 
the publication of Kalgutkar 
et al.38,95 Of course elimination 
of reactive metabolite forma-
tion will be of no benefit if it 
also eliminates the therapeutic 
effects of the drug.
Testing for GSH conjugates. 
One of the methods to detect 
the formation of electrophilic 
intermediates is to look for GSH 
conjugates of the drug. GSH 
is a major scavenger of reac-
tive metabolites and hence the 
detection of a GSH conjugate 
is an indication of the forma-
tion of a reactive intermediate. 
Formation of GSH conjugates 
can be detected by mass spec-
trometry, which, in turn, pro-
vides insight into the reactive 
metabolite structure.96,97 With 
the possible exception of acyl 
glucuronides and cyclic imin-
ium ions, most reactive metabo-
lites are generally short-lived 
and are not usually detectable 
in circulation. Their forma-
tion can often be inferred from 
stable conjugates obtained via 
reaction with the endogenous 
anti-oxidant GSH. The presence 
of the soft nucleophilic sulf-
hydryl group in GSH ensures 
efficient conjugation with soft 
electrophilic centers on reactive 
species (e.g., Michael acceptors, 
epoxides, arene oxides, and alkyl halides) yielding stable sulfhy-
dryl conjugates.38,98
Qualitative in vitro assessment of reactive-metabolite for-
mation usually involve ‘trapping’ studies conducted with 
NADPH-supplemented human liver microsomes and GSH; 
analysis of the resulting metabolites by mass spectrometry is 
employed to characterize the structure of GSH conjugates, which, 
in turn, provides insight into the reactive metabolite structure. 
Figure 10. Bioactivation of lumaricoxib to a reactive p-iminoquinone.
Figure 11. Bioactivation of acolbifene to reactive p-quinonemethide and p-diquinonemethide metabolites.www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  247
Considering that drug-metabolizing enzymes other than cyto-
chrome P450 [e.g., monoamine oxidases, aldehyde oxidase, 
alcohol dehydrogenases, myeloperoxidase, uridine 5’-diphospho-
glucuronosyl transferase (UGT), and sulfotransferases] are also 
capable of catalyzing bioactivation, due consideration must be 
given to the use of alternate metabolism vectors (e.g., S-9 frac-
tions, hepatocytes, neutrophils, monocytes, etc.), which support 
the activity of these enzymes. This is especially important in cases 
where multiple enzymatic and/or chemical steps may be involved 
in the production of the reactive metabolite. It is noteworthy to 
point out that not all reactive metabolites can be trapped with 
GSH. Hard electrophiles including DNA-reactive metabolites 
(e.g., electrophilic carbonyl compounds) will preferentially react 
with hard nucleophiles such as amines (e.g., semicarbazide and 
methoxylamine), amino acids (e.g., lysine), and DNA bases (e.g., 
guanine and cytosine) affording the corresponding Schiff bases.40 
Likewise, the cyanide anion, N-acetyllysine and methoxylamine 
are ‘hard’ nucleophiles that can be used to trap hard electro-
philes such as electrophilic iminium species that are generated 
via metabolism of tertiary amines.99,100
Usually GSH conjugate screening is performed on samples 
generated in vitro (using microsomes or hepatocytes), because in 
vivo, the conjugates might be transported to bile and destroyed 
by gut bacteria. This is more likely for high molecular weight 
drugs. Since non-microsomal drug metabolizing enzymes are 
also capable of catalyzing the bioactivation processes, due con-
sideration must be given to the use of metabolic systems other 
than liver microsomes such as liver cytosol, the S-9 fraction, or 
hepatocytes. In the case of drugs causing hematological toxicity 
such as agranulocytosis or bone mar-
row toxicity, the myeloperoxidase 
enzyme system is likely to be more 
appropriate.101
In the case of drugs that form 
short-lived free radical intermedi-
ates,102 the reactive intermediates can 
often be trapped using free radical 
trapping agents such as α-phenyl-N-
t-butylnitrone, which is commonly 
used to trap nitrogen free radi-
cals.18,103 Other spin trapping agents 
such as 2-methyl-2-nitroso-propane 
(MNP) to trap carbon-centered free 
radicals,104 5,5-dimethyl-pyrroline-
N-oxide (DMPO) to trap hydroxy, 
carbon-centered, and phenyl radi-
cals,105,106 and 5-diethoxyphospho-
ryl-5-methyl-1-pyrroline-N-oxide 
(DEPMPO) to trap S-centered radi-
cals such as glutathionyl (GS•) and 
the sulfite radical anion (SO3•),107 
have also been used. The trapped 
radicals can then be studied using 
electron spin resonance (ESR). 
Drugs that possibly form free radi-
cals such as aminoglutethimide,108 
procainamide,109 and phenytoin,18 can be detected using the 
above trapping agents.
Enzyme inactivation studies. As mentioned above, in certain 
cases the metabolites are so reactive that they do not escape the 
enzyme that formed them and covalently bind to the enzyme 
leading to irreversible inhibition.39 This is referred to as mech-
anism-based inactivation as metioned above, and in the case of 
P450 enzymes, it may result from irreversible alkylation of an 
active site amino acid or the heme prosthetic group or a com-
bination of both alkylation of heme inactivates P450, whereas 
amino acid alkylation does not always result in loss of cata-
lytic activity. Inactivation of P450 enzymes often translates into 
clinically important drug-drug interactions. Enzyme kinetic 
studies can provide clues to the existence of mechanism-based 
inhibition.
Covalent binding studies. An important method for detect-
ing and quantifying reactive metabolite formation is the use 
of radiolabelled drug to study the irreversible binding of the 
drug. Measurement of the amount of in vitro metabolism 
dependent covalent binding to biological tissue is possible if 
radiolabeled drug is available.99 The assay provides quantita-
tive estimates of radioactivity irreversibly bound to tissue but 
does not correctly provide information about the nature of 
covalently modified proteins as discussed below. Covalent-
binding studies can be performed in vivo as well. Either tissue 
or blood/plasma can be examined for the degree of covalent 
binding. However, covalent binding may require multiple dos-
ing to establish the true impact of the compound. Reactive 
metabolites formed after the first dose may be efficiently 
Figure 13. Bioactivation of zomepirac to a reactive arene oxide intermediate.
Figure 12. Bioactivation of carbamazepine to a reactive carbamazepine-10, 11-epoxide intermediate.248  Oxidative Medicine and Cellular Longevity  volume 3 issue 4
trapped by GSH and eliminated from the body. Once GSH is 
depleted, the extent of covalent binding with cellular macromol-
ecules may increase rapidly, resulting in toxicity. This is certainly 
the case with paracetamol where its reactive metabolite can cause 
direct hepatotoxicity upon an overdose, and yet paracetamol is 
rarely associated with idiosyncratic adverse drug reactions. This 
is because, at usual therapeutic doses, the phenolic group in 
paracetamol undergoes phase-II gluronidation and sulfonation, 
resulting in a small amount of NAPQI formed; most of which 
is scavenged by GSH before it binds to macromolecules. The 
hypothesis has been strengthened based on studies in mice which 
have shown that significant covalent binding does not occur until 
over 60–80% of the paracetamol overdose has been eliminated 
from the liver with concomitant reduction in GSH levels.37
An example of this overall approach is highlighted with   
studies on the potassium-channel opener, maxipost (BMS-
204352) (Fig. 16), which undergoes P450-mediated bioactivation 
in rats, dogs, and humans to generate a reactive ortho-quinone-
methide intermediate, which covalently binds to protein in vivo 
in animals and humans.110-111 Acidic hydrolysis of plasma col-
lected after intravenous administration of (14C)-BMS-204352 
to rats and human led to the characterization of a unique lysine 
conjugate of des-fluoro des-O-methyl BMS-204352 (Fig. 16).
Recent studies examining P450-mediated covalent binding 
of 18 drugs (nine hepatotoxins and nine non-hepatotoxins) to 
liver microsomes, S-9, and/or hepatocytes show no correlation 
between extent of covalent binding and toxicity.112,113 Indeed, 
covalent binding study can also make it possible to determine to 
which proteins the reactive metabolite is bound but this method 
can also give false negatives if the wrong metabolism system 
is used. For example the drug trimethoprim is bioactivated by 
neutrophils or myeloperoxidase, which is the major oxidative 
enzyme in these cells. So this enzyme system was used to inves-
tigate the bioactivation potential of the drug. Trimethoprim is 
also associated with liver toxicity and hence its investigation of 
bioactivation by P450 was also carried out. So it is important to 
use the right enzyme system depending upon the site of toxicity. 
Although there are major advantages to an in vitro system, the 
Figure 14. Bioactivation of diclofenac to a reactive acyl glucuronide.www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  249
potent drug, even if it is efficiently 
converted to a reactive metabolite, 
the amount will still be too low to 
represent a significant liability.114 
It is noteworthy to point out that 
there are no examples of drugs that 
are dosed at <20 mg/day that cause 
idiosyncratic adverse drug reactions 
(whether or not these agents are 
prone to bioactivation). There are 
many examples of two structurally 
related drugs that possess identical 
toxicophore susceptible to bioacti-
vation, but the one administered at 
the lower dose is safer than the one 
given at a higher dose. An illustration 
of this concept is evident with the 
antidiabetic thiazolidinedione drugs 
troglitazone (200–400 mg/day), 
rosiglitazone, and pioglitazone (<10 
mg/day). Troglitazone was with-
drawn from the United States market 
after numerous reported cases of liver 
failures requiring immediate liver 
transplantation or leading to death. 
In contrast, rosiglitazone and piogli-
tazone are devoid of the hepatotox-
icity associated with troglitazone.115 
Another consideration is the struc-
ture of the drug and presumed reac-
tive species and how hard it would be 
to eliminate reactive metabolite for-
mation and still have an active drug. 
In some cases such as proton pump 
inhibitors, the pharmacological 
activity depends on covalent binding 
of the drug to the enzyme; therefore, 
it would be impossible to eliminate 
covalent binding. Other risk versus 
benefit considerations in using this 
data are discussed below.
Immunochemical studies. It is also 
important to know what proteins are 
modified by a reactive metabolite. Although radiochemical meth-
ods can be used, it is more common to use immunochemical 
methods to determine which proteins are modified. This involves 
synthesis of an immunogen (i.e. reactive metabolite adduct 
conjugated to protein), against which antibodies are raised via 
immunization of animals with the immunogen. The antiserum 
is screened for anti-drug antibodies using an enzyme-linked 
immunosorbent assay. The antibody then can be used to identify 
haptenized biomacromolecules via Western blot analysis.116 The 
bands can then be cut out and the modified proteins identified 
by mass spectrometry. While this method can be a very power-
ful technique for the identification and characterization of cellu-
lar constituents that have undergone covalent modification by a 
data cannot be extrapolated to predict what will happen in vivo 
because there are several in vivo detoxifying systems such as GSH 
and glutathione transferase that may not be present in the in vitro 
system.11 Hence the amount of covalent binding observed in vivo 
might be a lower than that in vitro.
Merck has conducted covalent binding studies with various 
compounds and has proposed a benchmark of 50 pmole/mg of 
microsomal protein. If the amount of binding is greater than this 
amount, consideration would be given to modifying the structure 
to decrease the amount of covalent binding.99 However, there is 
no firm limit because several other considerations enter into the 
final decision of how much covalent binding is permissible. One 
consideration is the daily dose of the drug because, if it is a very 
Figure 15. Bioactivation of the antifungal compound NDPS to a reactive O-sulfate.
Figure 16. Proposed pathways for biotransformation of [14C]BMS-204352 in humans.250  Oxidative Medicine and Cellular Longevity  volume 3 issue 4
reactive metabolites, a strategy for identifying and potentially 
minimizing their formation via rational and iterative medicinal 
chemistry efforts seems logical in certain cases.124,125 It is note-
worthy to point out that reactive-metabolite formation is only 
one aspect of the overall risk/benefit assessment for advancing 
a drug candidate into development. Consequently, bioactiva-
tion data (reactive metabolite trapping and/or covalent binding) 
needs to be placed in a broader context with due consideration 
given to the following points (Fig. 17):
1.  Is the drug intended to address a previously unmet medical 
need or a lifethreatening disease?
2.  Is the drug candidate intended to provide proof-of-mecha-
nism for a novel target?
3.  Is the drug intended for acute or chronic use?
4.  Is the clinical dose predicted to be low?
5.  What is the intended patient population (e.g., would it 
be given to immunecomprised patients or patients with 
impaired liver functions)?
6.  Are there alternate chemical series with comparable pharma-
cologic and pharmacokinetic attributes, wherein bioactiva-
tion liability is minimized or eliminated?
7.  Is there an alternative (higher affinity but innocuous) route 
of metabolism within the drug candidate that minimizes 
bioactivation liability associated with the compound?
8.  Is metabolism the exclusive route of elimination? What is the 
likelihood of nonmetabolic elimination processes (e.g., renal 
and/or biliary excretion of unchanged parent) in humans?
If the benefits outweigh the risk, the compounds can be 
advanced cautiously. In conclusions, a critical point of this review 
is the possibility that the reactive metabolites must be considered 
as “structural alerts” or “toxicophores” that should be avoided in 
drug development. Then the question is whether drug candidates 
that can form reactive metabolites must be totally avoided? There 
is no simple answer to this question. At least two major factors 
seem to be important: the dose of the drug and the amount of 
covalent binding. Any drug that is taken at a total dose of 20 
mg/day or less is unlikely to be associated with a high incidence 
Figure 17. Schematic illustration of the risk and benefits for drug devel-
opment. See text for explanation. 
reactive metabolite, it would be impractical to use as a screening 
tool because an antibody would have to be generated to each drug 
candidate. It is also not quantitative.
Unfortunately, without a valid animal model, it is practically 
impossible to determine whether a specific reactive metabolite is 
responsible for a given idiosyncratic drug reaction. Therefore, we 
are left with trying to infer causality. Given their unpredictable 
nature, idiosyncratic drug reactions are generally not detected 
until the drug is released onto the market because clinical tri-
als involve a limited number of subjects. If a drug is found to be 
associated with an unacceptable risk of serious idiosyncratic drug 
reactions it will cause a huge financial loss to the pharmaceutical 
company involved because drug development is a very expensive 
process. The current cost of drug development has been pegged 
at $1.3 billion US as per a 2009 report.117 Even though one can 
minimize the ability of drugs to cause bioactivation, it is hard to 
predict which compounds will cause idiosyncratic drug reactions 
because not all covalent binding is associated with the same risk.
The existing in vitro tests are not able to mimic the complex-
ity of in vivo biological systems, and our present mechanistic 
understanding of idiosyncratic drug reactions is quite superfi-
cial. Therefore, animal models are an essential tool for mecha-
nistic studies. They might also be used to screen compounds in 
development with similar structures to predict which are most 
likely to cause idiosyncratic drug reactions. There are currently 
only two practical animal models that appear to involve the 
same mechanism as the idiosyncratic drug reactions that occur 
in humans. They are nevirapine-induced skin rash,118,119 and 
D-penicillamine-induced autoimmunity.11,120 Development of 
further animal models is necessary to understand the mecha-
nisms underlying idiosyncratic drug reactions. It is unlikely that 
significant progress will be made in preventing idiosyncratic drug 
reactions until we have a better mechanistic understanding of 
these adverse reactions.
There are also other animal models of idiosyncratic drug reac-
tions such as propylthiouracil-induced autoimmunity in cats;121 
however, cats are not a practical species to work with. Another 
model is halothane-induced liver injury in guinea pigs;122 how-
ever, in this model halothane exposure never leads to significant 
damage and is milder on re-exposure rather than being worse as 
occurs in humans. A good discussion of these animal models is 
available in the review by Shenton et al.123 Nevertheless, there are 
not many models of idiosyncratic drug reactions and developing 
more animal models would significantly contribute to a better 
understanding of underlying mechanisms associated with idio-
syncratic drug reactions and ultimately help in the development 
of safer drugs.
Risk Versus Benefit
Testing of drug candidates for the formation of the reactive 
metabolites would likely result in safer drugs entering devel-
opment. It can also result in false positives and false negatives. 
Nevertheless a decision has to be reached whether to advance 
compounds to development. Until we develop a better under-
standing of the risk of toxicity arising from the formation of www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  251
of idiosyncratic drug reactions in humans.114 Sometimes the mar-
keted drug may contain a structural alert or toxicophore but still 
not cause a significant incidence of idiosyncratic drug reactions. 
Again, total exposure to a reactive metabolite is important. One 
possible reason for this is that the toxicophore is not the primary 
site of metabolism and therefore not much of the potential reac-
tive metabolite is formed. Even if bioactivation is the major path-
way in vitro, a microsomal incubation does not contain all of 
the metabolic enzymes, and there may be other major clearance 
pathways in vivo that do not lead to a reactive metabolite. An 
example of this is raloxifene; in vitro using microsome system, 
the major pathway is bioactivation of the phenolic metabolite 
leading to quinone intermediate whereas in vivo the principal 
mode of clearance is through the glucuronidation of phenolic 
metabolites rather than the bioactivation. It is associated with 
low incidence of idiosyncratic drug reactions presumably because 
of the protective effect of glucuronidation.39,126 Another reason 
could be that the principle route of clearance is through a non-
metabolic pathway such as renal elimination.38
Examples of strategies that could be followed in drug design to 
minimize the metabolic liability associated with reactive metabo-
lite formation are: (a) Replacement of the structural alert with 
substituents that are resistant to metabolism or can be metabo-
lized to nonreactive species; (b) Blocking the functional groups 
that are known to undergo bioactivation by a functional group 
that does not undergo activation; (c) Incorporating a bulky 
substituent close to the site of metabolism so that metabolism 
could not occur at the site of metabolic activation. Of course 
elimination of reactive metabolite formation will be of no ben-
efit if it also eliminates the therapeutic effects of the drug and, 
therefore, it is essential that the pharmacological effects of drug 
candidates be tested at each step in the optimization of the 
structure.
Finally, because it is now widely appreciated that reactive 
metabolites, as opposed to the parent molecules from which 
they are derived, are responsible for the pathogenesis of some 
idiosyncratic adverse drug reactions, it is essential to determine 
exactly how they induce idiosyncratic adverse drug reactions, 
and what factors determine which reactive metabolites are most 
likely to cause idiosyncratic adverse drug reactions, and which 
patients are at highest risk. This requires the development of 
animal models and the identification of which target proteins 
are most important for the induction of idiosyncratic adverse 
drug reactions. Knowledge gained through these processes will 
be useful to unravel the mysteries of the fascinating research 
area of idiosyncratic or bizarre adverse drug reactions. This will, 
in turn, help us to design and bring safer drugs to the market.
Acknowledgements
Editorial assistance by Prof. Kenneth Maiese is acknowledged.
References
1.  Olson H, Betton G, Robinson D, Thomas K, Monro 
A, Kolaja G, et al. Concordance of the toxicity of phar-
maceuticals in humans and in animals. Regul Toxicol 
Pharmacol 2000; 32:56-67.
2.  Srivastava A, Maggs JL, Antoine DJ, Williams DP, 
Smith DA, Park BK. Role of reactive metabolites in 
drug-induced hepatotoxicity. Handb Exp Pharmacol 
2010; 196:165-94. 
3.  Wolf R, Orion E, Marcos B, Matz H. Life-threatening 
acute adverse cutaneous drug reactions. Clin Dermatol 
2005; 23:171-81.
4.  Sevketoglu E, Hatipoglu S, Akman M, Bicer S. Toxic 
epidermal necrolysis in a child after carbamazepine dos-
age increment. Pediatr Emerg Care  2009; 25:93-5.
5.  Svensson CK. Biotransformation of drugs in human 
skin. Drug Metab Dispos 2009; 37:247-53.
6.  Handoko KB, Souverein PC, van Staa TP, Meyboom 
RH, Leufkens HG, Egberts TC, et al. Risk of aplastic 
anemia in patients using antiepileptic drugs. Epilepsia 
2006; 47:1232-6. 
7.  Andrès E, Federici L, Weitten T, Vogel T, Alt M. 
Recognition and management of drug-induced blood 
cytopenias: the example of drug-induced acute neutro-
penia and agranulocytosis. Expert Opin Drug Saf 2008; 
7:481-9.
8.  Kaplowitz N. Drug-induced liver injury. Clin Infect 
Dis 2004; 38: S44-8.
9.  Levi PE, Hodgson E. Reactive metabolites and toxicity, 
in Introduction to Biochemical Toxicology, 3rd ed., 
(Hodgson E, Smart RC, eds), Wiley, New York 2001; 
199-220.
10.  Conney AH. In memoriam: James A. Miller (1915-
2000). Cancer Res 2001; 61:3847-8.
11.  Uetrecht J. Idiosyncratic drug reactions: current under-
standing. Annu Rev Pharmacol Toxicol 2007; 47:513-39. 
12.  Ikehata K, Duzhak TG, Galeva NA, Ji T, Koen YM, 
Hanzlik RP. Protein targets of reactive metabolites of 
thiobenzamide in rat liver in vivo. Chem Res Toxicol 
2008; 21:1432-42.
13.  Amacher DE. Reactive intermediates and the patho-
genesis of adverse drug reactions: the toxicology per-
spective. Curr Drug Metab 2006; 7:219-29.
14.  Wells PG, McCallum GP, Chen CS, Henderson JT, Lee 
CJ, Perstin J, et al. Oxidative stress in developmental 
origins of disease: teratogenesis, neurodevelopmental 
deficits, and cancer. Toxicol Sci 2009; 108:4-18.
15.  Wells PG, Lee CJ, McCallum GP, Perstin J, Harper PA. 
Receptor- and reactive intermediate-mediated mecha-
nisms of teratogenesis. Handb Exp Pharmacol 2010; 
196:131-62.
16. Skipper PL, Kim MY, Sun HL, Wogan GN, 
Tannenbaum SR. Monocyclic aromatic amines as 
potential human carcinogens: old is new again. 
Carcinogenesis 2010; 31:50-8.
17.  Clayden J, Greeves N, Warren S, Wothers P. Organic 
Chemistry, 1th ed., Oxford University Press Inc.: New 
York, USA 2001.
18.  Kubow S, Wells PG. In vitro bioactivation of phenytoin 
to a reactive free radical intermediate by prostaglandin 
synthetase, horseradish peroxidase, and thyroid peroxi-
dase. Mol Pharmacol 1989; 35:504-11.
19.  Sun Q, Zhu R, Foss FW Jr, Macdonald TL. In vitro 
metabolism of a model cyclopropylamine to reactive 
intermediate: insights into trovafloxacin-induced hepa-
totoxicity. Chem Res Toxicol 2008; 21:711-9.
20.  Beckman JS. Understanding peroxynitrite biochemistry 
and its potential for treating human diseases. Arch 
Biochem Biophys 2009; 484:114-6.
21.  Vanhoutte PM. How we learned to say NO. Arterioscler 
Thromb Vasc Biol 2009; 29:1156-60.
22.  Bedard K, Krause KH. The NOX family of ROS-
generating NADPH oxidases: physiology and patho-
physiology. Physiol Rev 2007; 87:245-313.
23.  Wingler K, Schmidt HH. Good stress, bad stress-the 
delicate balance in the vasculature. Dtsch Arztebl Int 
2009; 106:677-84.
24.  Gutteridge JM, Halliwell B. Antioxidants: Molecules, 
medicines, and myths. Biochem Biophys Res Commun 
2010; 393:561-4.
25.  McNally JS, Davis ME, Giddens DP, Saha A, Hwang 
J, Dikalov S, et al. Role of xanthine oxidoreductase and 
NAD(P)H oxidase in endothelial superoxide produc-
tion in response to oscillatory shear stress. Am J Physiol 
Heart Circ Physiol 2003; 285:H2290-7. 
26.  Dalle-Donne I, Rossi R, Colombo R, Giustarini D, 
Milzani A. Biomarkers of oxidative damage in human 
disease. Clin Chem 2006; 52:601-23.
27.  Fisher-Wellman K, Bell HK, Bloomer RJ. Oxidative 
stress and antioxidant defense mechanisms linked to 
exercise during cardiopulmonary and metabolic disor-
ders. Oxid Med Cell Longev 2009; 2:43-51.
28.  Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh 
K, Colucci WS. Role of oxidative stress in myocar-
dial hypertrophy and failure. J Mol Cell Cardiol 2002; 
34:379-88.
29.  Elahi MM, Yu Xiang Kong YX, Matata BM. Oxidative 
stress as a mediator of cardiovascular disease. Oxid Med 
Cell Longev 2009; 2:259-69.
30.  Afanas’ev I. Reactive oxygen species and age-related 
genes p66shc, Sirtuin, FOX03 and Klotho in senes-
cence. Oxid Med Cell Longev 2010; 3:77-85.
31.  Essick EE, Sam F. Oxidative stress and autophagy in 
cardiac disease, neurological disorders, aging and can-
cer. Oxid Med Cell Longev 2010; 3:168-77. 
32.  Jung-Hynes B, Reiter RJ, Ahmad N. Sirtuins, melato-
nin and circadian rhythms: building a bridge between 
aging and cancer. J Pineal Res 2010; 48:9-19.
33.  Calabrese V, Cornelius C, Mancuso C, Lentile R, 
Stella AM, Butterfield DA. Redox homeostasis and 
cellular stress response in aging and neurodegeneration. 
Methods Mol Biol 2010; 610:285-308.
34.  Larson AM. Acetaminophen hepatotoxicity. Clin Liver 
Dis 2007; 11:525-48.
35.  Jollow DJ, Mitchell JR, Potter WZ, Davis DC, Gillette 
JR, Brodie BB. Acetaminophen-induced hepatic necro-
sis. II. Role of covalent binding in vivo. J Pharmacol 
Exp Ther 1973; 187:195-202.
36.  Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette 
JR, Brodie BB. Acetaminophen-induced hepatic necro-
sis. I. Role of drug metabolism. J Pharmacol Exp Ther 
1973; 187:185-94.252  Oxidative Medicine and Cellular Longevity  volume 3 issue 4
37.  Dahlin DC, Miwa GT, Lu AY, Nelson SD. N-acetyl-
p-benzoquinone imine: a cytochrome P-450-mediated 
oxidation product of acetaminophen. Proc Natl Acad 
Sci USA 1984; 81:1327-31.
38.  Kalgutkar AS, Soglia JR. Minimising the potential for 
metabolic activation in drug discovery. Expert Opin 
Drug Metab Toxicol 2005; 1:91-142.
39.  Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, 
DiNinno FP, et al. Cytochrome P450 3A4-mediated 
bioactivation of raloxifene: irreversible enzyme inhibi-
tion and thiol adduct formation. Chem Res Toxicol 
2002; 15:907-14.
40.  Kalgutkar AS, Dalvie DK, Aubrecht J, Smith EB, 
Coffing SL, Cheung JR, et al. Genotoxicity of 
2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 
5-hydroxytryptamine2c receptor agonist for the treat-
ment of obesity: role of metabolic activation. Drug 
Metab Dispos 2007; 35:848-58. 
41.  Schmassmann-Suhijar D, Bullingham R, Gasser R, 
Schmutz J, Haefeli WE. Rhabdomyolysis due to inter-
action of simvastatin with mibefradil. Lancet 1998; 
351:1929-30.
42.  Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, 
Lu P, et al. Metabolic interactions between mibefradil 
and HMG-CoA reductase inhibitors: an in vitro 
investigation with human liver preparations. Br J Clin 
Pharmacol 1999; 47:291-8. 
43.  Almeida JC, Grimsley EW. Coma from the health food 
store: interaction between kava and alprazolam. Ann 
Intern Med 1996; 125:940-1.
44.  Clouatre DL. Kava kava: examining new reports of 
toxicity. Toxicol Lett 2004; 150:85-96.
45.  Izzo AA, Ernst E. Interactions between herbal medi-
cines and prescribed drugs: an updated systematic 
review. Drugs 2009; 69:1777-98.
46.  Singh YN, Singh NN. Therapeutic potential of kava in 
the treatment of anxiety disorders. CNS Drugs 2002; 
16: 731-43.
47.  Mathews JM, Etheridge AS, Black SR. Inhibition of 
human cytochrome P450 activities by kava extract and 
kavalactones. Drug Metab Dispos 2002; 30:1153-7.
48.  Johnson BM, Qiu SX, Zhang S, Zhang F, Burdette 
JE, Yu L, et al. Identification of novel electrophilic 
metabolites of piper methysticum Forst (Kava). Chem 
Res Toxicol 2003; 16:733-40.
49.  Fieser LF. Carcinogenic activity, structure, and chemical 
reactivity of polynuclear aromatic hydrocarbons. Am J 
Cancer 1938; 34:37-I24.
50.  Miller EC, Miller JA. The presence and significance of 
bound aminoazo dyes in the livers of rats fed p-dimeth-
yl- aminoazobenzene. Cancer Res 1947; 7:468-80.
51.  Thybaud V, Aardema M, Clements J, Dearfield K, 
Galloway S, Hayashi M, et al. Expert working group 
on hazard identification and risk assessment in relation 
to in vitro testing. Mutat Res 2007; 627:41-58.
52.  Ku WW, Bigger A, Brambilla G, Glatt H, Gocke 
E, Guzzie PJ, et al. Strategy Expert Group, IWGT. 
Strategy for genotoxicity testing-metabolic consider-
ations. Mutat Res 2007; 627:59-77.
53.  Woosley RL, Drayer DE, Reidenberg MM, Nies AS, 
Carr K, Oates JA. Effect of acetylator phenotype on 
the rate at which procainamide induces antinuclear 
antibodies and the lupus syndrome. N Engl J Med 
1978; 298:1157-9.
54.  Wolkenstein P, Carrière V, Charue D, Bastuji-Garin 
S, Revuz J, Roujeau JC, et al. A slow acetylator geno-
type is a risk factor for sulphonamide-induced toxic 
epidermal necrolysis and Stevens-Johnson syndrome. 
Pharmacogenetics 1995; 5:255-8.
55.  Uetrecht JP. Reactivity and possible significance of 
hydroxylamine and nitroso metabolites of procain-
amide. J Pharmacol Exp Ther 1985; 232:420-5.
56.  Cribb AE, Miller M, Leeder JS, Hill J, Spielberg SP. 
Reactions of the nitroso and hydroxylamine metabo-
lites of sulfamethoxazole with reduced glutathione. 
Implications for idiosyncratic toxicity. Drug Metab 
Dispos 1991; 19:900-6.
57.  Park EY, Cho IJ, Kim SG. Transactivation of the 
PPAR-responsive enhancer module in chemopreven-
tive glutathione S-transferase gene by the peroxisome 
proliferator-activated receptor-gamma and retinoid X 
receptor heterodimer. Cancer Res 2004; 64:3701-13.
58.  Ueda K, Ishitsu T, Seo T, Ueda N, Murata T, Hori M, 
et al. Glutathione S-transferase M1 null genotype as a 
risk factor for carbamazepine-induced mild hepatotox-
icity. Pharmacogenomics 2007; 8:435-42.
59.  Buckley NA, Srinivasan J. Should a lower treatment 
line be used when treating paracetamol poisoning in 
patients with chronic alcoholism?: a case for. Drug Saf 
2002; 25:619-24.
60.  Bolton JL, Trush MA, Penning TM, Dryhurst G, 
Monks TJ. Role of quinines in toxicology. Chem Res 
Toxicol 2000; 13:135-60.
61.  Monks TJ, Jones DC. The metabolism and toxicity 
of quinones, quinonimines, quinone methides, and 
quinone-thioethers. Curr Drug Metab 2002; 3:425-38.
62.  Hayasaki Y, Itoh S, Kato M, Furuhama K. Mutagenesis 
induced by 12 quinolone antibacterial agents in 
Escherichia coli WP2uvrA/pKM101. Toxicol In Vitro 
2006; 20:342-26.
63.  Attia SM. Use of centromeric and telomeric DNA 
probes in in situ hybridization for differentiation of 
micronuclei induced by lomefloxacin. Environ Mol 
Mutagen 2009; 50:394-403.
64.  Levay G, Pongracz K, Bodell WJ. Detection of DNA 
adducts in HL-60 cells treated with hydroquinone and 
p-benzoquinone by 32P-postlabeling. Carcinogenesis 
1991; 12:1181-6.
65.  Chen H, Eastmond DA. Synergistic increase in chro-
mosomal breakage within the euchromatin induced by 
an interaction of the benzene metabolites phenol and 
hydroquinone in mice. Carcinogenesis 1995; 16:1963-9.
66.  Hande KR. Etoposide: four decades of development 
of a topoisomerase II inhibitor. Eur J Cancer 1998; 
34:1514-21.
67.  Turner SD, Wijnhoven SW, Tinwell H, Lashford LS, 
Rafferty JA, Ashby J, et al. Assays to predict the genotox-
icity of the chromosomal mutagen etoposide - focussing 
on the best assay. Mutat Res 2001; 493:139-47.
68.  Attia SM, Schmid TE, Badary OA, Hamada FM, Adler 
I-D. Molecular cytogenetic analysis in mouse sperm of 
chemically induced aneuploidy: studies with topoisom-
erase II inhibitors. Mutat Res 2002; 520:1-13.
69.  Attia SM, Kliesch U, Schriever-Schwemmer G, Badary 
OA, Hamada FM, Adler I-D. Etoposide and merbar-
one are clastogenic and aneugenic in the mouse bone 
marrow micronucleus test complemented by fluo-
rescence in situ hybridization with the mouse minor 
satellite DNA probe. Environ Mol Mutagen 2003; 
41:99-103.
70.  Choudhury RC, Palo AK, Sahu PJ. Cytogenetic risk 
assessment of etoposide from mouse bone marrow. 
Appl Toxicol 2004; 24:115-22.
71.  Felix CA. Leukemias related to treatment with DNA 
topoisomerase II inhibitors. Med Pediatr Oncol 2001; 
36:525-35.
72.  Felix CA, Kolaris CP, Osheroff N. Topoisomerase II 
and the etiology of chromosomal translocations. DNA 
Rep 2006; 5: 1093-8.
73.  Sung PA, Libura J, Richardson C. Etoposide and 
illegitimate DNA double-strand break repair in the 
generation of MLL translocations: new insights and 
new questions. DNA Rep 2006; 5:1109-18.
74.  Kagan VE, Yalowich JC, Borisenko GG, Tyurina YY, 
Tyurin VA, Thampatty P, et al. Mechanism-based 
chemopreventive strategies against etoposide-induced 
acute myeloid leukemia: free radical/antioxidant 
approach. Mol Pharmacol 1999; 56:494-506.
75.  Kagan VE, Kuzmenko AI, Tyurina YY, Shvedova AA, 
Matsura T, Yalowich JC. Pro-oxidant and antioxidant 
mechanisms of etoposide in HL-60 cells: role of myelo-
peroxidase. Cancer Res 2001; 61:7777-84.
76.  Ritov VB, Goldman R, Stoyanovsky DA, Menshikova 
EV, Kagan VE. Antioxidant paradoxes of phenolic 
compounds: peroxyl radical scavenger and lipid antioxi-
dant, etoposide (VP-16), inhibits sarcoplasmic reticu-
lum Ca(2+)-ATPase via thiol oxidation by its phenoxyl 
radical. Arch Biochem Biophys 1995; 321:140-52.
77.  Siitonen T, Alaruikka P, Mantymaa P, Savolainen ER, 
Kavanagh TJ, Krejsa CM, et al. Protection of acute 
myeloblastic leukemia cells against apoptotic cell death 
by high glutathione and gamma-glutamylcysteine syn-
thetase levels during etoposide-induced oxidative stress. 
Ann Oncol 1999; 10:1361-7.
78.  Attia SM, Al-Anteet AA, AL-Rasheed NM, Alhaider 
AA, Al-Harbi MM. Protection of mouse bone marrow 
from etoposide-induced genomic damage by dexrazox-
ane. Cancer Chemother Pharmacol 2009; 64:837-45.
79.  Erve JC, Svensson MA, von Euler-Chelpin H, Klasson-
Wehler E. Characterization of glutathione conjugates of 
the remoxipride hydroquinone metabolite NCQ-344 
formed in vitro and detection following oxidation by 
human neutrophils. Chem Res Toxicol 2004; 17:564-71.
80.  Naisbitt DJ, Williams DP, O’Neill PM, Maggs JL, 
Willock DJ, Pirmohamed M, et al. Metabolism-
dependent neutrophil cytotoxicity of amodiaquine: A 
comparison with pyronaridine and related antimalarial 
drugs. Chem Res Toxicol 1998; 11:1586-95.
81.  Albano E, Rundgren M, Harvison PJ, Nelson SD, 
Moldeus P. Mechanisms of N-acetyl-p-benzoquinone 
imine cytotoxicity. Mol Pharmacol 1985; 28:306-11.
82.  Li Y, Slatter JG, Zhang Z, Doss GA, Braun MP, Stearns 
RA, et al. In vitro metabolic activation of lumira-
coxib in rat and human liver preparations. Drug Metab 
Dispos 2008; 36:469-73.
83.  Thompson DC, Perera K, Krol ES, Bolton JL. 
o-Methoxy-4-alkylphenols that form quinone methides 
of intermediate reactivity are the most toxic in rat liver 
slices. Chem Res Toxicol 1995; 8:323-7.
84.  Liu J, Liu H, van Breemen RB, Thatcher GR, Bolton 
JL. Bioactivation of the selective estrogen receptor 
modulator acolbifene to quinone methides. Chem Res 
Toxicol 2005; 18:174-82.
85.  Pirmohamed M, Kitteringham NR, Breckenridge AM, 
Park BK. The effect of enzyme induction on the cyto-
chrome P450-mediated bioactivation of carbamazepine 
by mouse liver microsomes. Biochem Pharmacol 1992; 
44:2307-14.
86.  Pearce RE, Lu W, Wang Y, Uetrecht JP, Correia MA, 
Leeder JS. Pathways of carbamazepine bioactivation 
in vitro. III. The role of human cytochrome P450 
enzymes in the formation of 2,3-dihydroxycarbamaze-
pine. Drug Metab Dispos 2008; 36:1637-49.
87.  Chen Q, Doss GA, Tung EC, Liu W, Tang YS, Braun 
MP, et al. Evidence for the bioactivation of zomepirac 
and tolmetin by an oxidative pathway: identification of 
glutathione adducts in vitro in human liver microsomes 
and in vivo in rats. Drug Metab Dispos 2006; 34:145-51.
88.  Hargus SJ, Amouzedeh HR, Pumford NR, Myers TG, 
McCoy SC, Pohl LR. Metabolic activation and immu-
nochemical localization of liver protein adducts of the 
nonsteroidal anti-inflammatory drug diclofenac. Chem 
Res Toxicol 1994; 7:575-82.
89.  Ware JA, Graf ML, Martin BM, Lustberg LR, Pohl 
LR. Immunochemical detection and identification of 
protein adducts of diclofenac in the small intestine 
of rats: possible role in allergic reactions. Chem Res 
Toxicol 1998; 11:164-71.
90.  Li C, Benet LZ, Grillo MP. Studies on the chemical 
reactivity of 2-phenylpropionic acid 1-O-acyl glucuro-
nide and S-acyl-CoA thioester metabolites. Chem Res 
Toxicol 2002; 15:1309-17.
91.  Glatt H, Engelke CE, Pabel U, Teubner W, Jones AL, 
Coughtrie MW, et al. Sulfotransferases: genetics and 
role in toxicology. Toxicol Lett 2000; 112-113:341-8.
92.  Cui D, Rankin GO, Harvison PJ. Metabolism of the 
nephrotoxicant N-(3,5-dichlorophenyl)succinimide in 
rats: evidence for bioactivation through alcohol-Ogluc-
uronidation and O-sulfation. Chem Res Toxicol 2005; 
18: 991-1003.www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  253
93.  Uetrecht J. N-oxidation of drugs associated with 
idiosyncratic drug reactions. Drug Metab Rev 2002; 
34:651-65.
94.  Hofstra AH, Matassa LC, Uetrecht JP. Metabolism 
of hydralazine by activated leukocytes: implications 
for hydralazine induced lupus. J Rheumatol 1991; 
18:1673-80.
95.  Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, 
Callegari E, Henne KR, et al. A comprehensive listing 
of bioactivation pathways of organic functional groups. 
Curr Drug Metab 2005; 6:161-225.
96.  Mahajan MK. Evans CA. Dual negative precursor 
ion scan approach for rapid detection of glutathione 
conjugates using liquid chromatography/tandem mass 
spectrometry. Rapid Commun Mass Spectrom 2008; 
22:1032-40.
97.  Leblanc A, Shiao TC, Roy R, Sleno L. Improved detec-
tion of reactive metabolites with a bromine-containing 
glutathione analog using mass defect and isotope pat-
tern matching. Rapid Commun Mass Spectrom 2010; 
24:1241-50.
98.  Baillie TA, Davis MR. Mass spectrometry in the 
analysis of glutathione conjugates. Biol Mass Spectrom 
1993; 22:319-25.
99.  Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. 
Drug-protein adducts: an industry perspective on 
minimizing the potential for drug bioactivation in drug 
discovery and development. Chem Res Toxicol 2004; 
17:3-16.
100. Argoti D, Liang L, Conteh A, Chen L, Bershas D, Yu 
CP, et al. Cyanide trapping of iminium ion reactive 
intermediates followed by detection and structure iden-
tification using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). Chem Res Toxicol 2005; 
18:1537-44.
101. Furst SM, Uetrecht JP. Carbamazepine metabolism to 
a reactive intermediate by the myeloperoxidase system 
of activated neutrophils. Biochem Pharmacol 1993; 
45:1267-75.
102. Mason RP, Kadiiska MB. In vivo spin trapping of 
free radical metabolites of drugs and toxic chemicals 
utilizing ex vivo detection in: Biomedical EPR, Part A: 
Free Radicals, Metals, Medicine, and Physiology 2006; 
93-109.
103. Kubow S, Janzen EG, Bray TM. Spin-trapping of free 
radicals formed during in vitro and in vivo metabolism 
of 3-methylindole. J Biol Chem 1984; 259:4447-51.
104. Krings U, Andersen ML, Berger RG. In vivo ESR spin 
trapping detection of carbon-centered alpha-Farnesene 
radicals. J Agric Food Chem 2008; 56:4333-9.
105. Kadiiska MB, De Costa KS, Mason RP, Mathews JM. 
Reduction of 1,3-diphenyl-1-triazene by rat hepatic 
microsomes, by cecal microflora, and in rats generates 
the phenyl radical metabolite: nn ESR spin-trapping 
investigation. Chem Res Toxicol 2000; 13:1082-6.
106. Chou DS, Hsiao G, Shen MY, Tsai YJ, Chen TF, Sheu 
JR. ESR spin trapping of a carbon-centered free radical 
from agonist-stimulated human platelets. Free Radic 
Biol Med 2005; 39:237-48.
107. Liu KJ, Miyake M, Panz T, Swartz H. Evaluation of 
DEPMPO as a spin trapping agent in biological sys-
tems. Free Radic Biol Med 1999; 26:714-21.
108. Siraki AG, Bonini MG, Jiang J, Ehrenshaft M, Mason 
RP. Aminoglutethimideinduced protein free radical for-
mation on myeloperoxidase: a potential mechanism of 
agranulocytosis. Chem Res Toxicol 2007; 20:1038-45.
109.  Siraki AG, Deterding LJ, Bonini MG, Jiang J, 
Ehrenshaft M, Tomer KB, et al. Procainamide, but not 
N-acetylprocainamide, induces protein free radical for-
mation on myeloperoxidase: a potential mechanism of 
agranulocytosis. Chem Res Toxicol 2008; 21:1143-53.
110. Zhang D, Ogan M, Gedamke R, Roongta V, Dai R, 
Zhu M, et al. Protein covalent binding of maxipost 
through a cytochrome P450-mediated ortho-quinone 
methide intermediate in rats. Drug Metab Dispos 
2003; 31:837-45.
111. Zhang D, Krishna R, Wang L, Zeng J, Mitroka J, Dai R, 
et al. Metabolism, pharmacokinetics, and protein cova-
lent binding of radiolabeled MaxiPost (BMS-204352) in 
humans. Drug Metab Dispos 2005; 33:83-93.
112. Obach RS, Kalgutkar AS, Soglia JR, Zhao SX. Can in 
vitro metabolism-dependent covalent binding data in 
liver microsomes distinguish hepatotoxic from non-
hepatotoxic drugs? An analysis of 18 drugs with con-
sideration of intrinsic clearance and daily dose. Chem 
Res Toxicol 2008; 21:1814-22. 
113. Bauman JN, Kelly JM, Tripathy S, Zhao SX, Lam WW, 
Kalgutkar AS, et al. Can in vitro metabolism-depen-
dent covalent binding data distinguish hepatotoxic 
from nonhepatotoxic drugs? An analysis using human 
hepatocytes and liver S-9 fraction. Chem Res Toxicol 
2009; 22:332-40.
114. Uetrecht J. Screening for the potential of a drug candi-
date to cause idiosyncratic drug reactions. Drug Discov 
Today 2003; 8:832-7. 
115. Alvarez-Sanchez R, Montavon F, Hartung T, Pähler A. 
Thiazolidinedione bioactivation: a comparison of the 
bioactivation potentials of troglitazone, rosiglitazone, 
and pioglitazone using stable isotope-labeled analogues 
and liquid chromatography tandem mass spectrometry. 
Chem Res Toxicol 2006; 19:1106-16.
116.  Lai WG, Gardner I, Zahid N, Uetrecht JP. Bioactivation 
and covalent binding of hydroxyfluperlapine in human 
neutrophils: implications for fluperlapineinduced 
agranulocytosis. Drug Metab Dispos 2000; 28:255-63.
117. Collier R. Drug development cost estimates hard to 
swallow. CMAJ 2009; 180:279-80.
118. Shenton JM, Teranishi M, Abu-Asab MS, Yager JA, 
Uetrecht JP. Characterization of a potential animal 
model of an idiosyncratic drug reaction: nevirapine-
induced skin rash in the rat. Chem Res Toxicol 2003; 
16:1078-89.
119.  Shenton JM, Popovic M, Uetrecht JP. In Drug 
Hypersensitivity. WJ. Pichler ED., Basel, Karger 2007; 
115-28.
120. Donker AJ, Venuto RC, Vladutiu AO, Brentjens JR, 
Andres GA. Effects of prolonged administration of 
D-penicillamine or captopril in various strains of rats. 
Brown Norway rats treated with D-penicillamine 
develop autoantibodies, circulating immune complex-
es, and disseminated intravascular coagulation. Clin 
Immunol Immunopathol 1984; 30:142-55.
121. Peterson ME, Hurvitz AI, Leib MS, Cavanagh PG, 
Dutton RE. Propylthiouracil-associated hemolytic ane-
mia, thrombocytopenia, and antinuclear antibodies in 
cats with hyperthyroidism. J Am Vet Med Assoc 1984; 
184:806-8.
122. Furst SM, Luedke D, Gaw HH, Reich R, Gandolfi AJ. 
Demonstration of a cellular immune response in hal-
othane-exposed guinea pigs. Toxicol Appl Pharmacol 
1997; 143:245-55.
123. Shenton JM, Chen J, Uetrecht JP. Animal models of 
idiosyncratic drug reactions. Chem Biol Interact 2004; 
150:53-70.
124. Kumar S, Kassahun K, Tschirret-Guth RA, Mitra K, 
Baillie TA. Minimizing metabolic activation during 
pharmaceutical lead optimization: progress, knowledge 
gaps and future directions. Curr Opin Drug Discov 
Devel 2008; 11:43-52.
125. Kumar S, Mitra K, Kassahun K, Baillie TA. Approaches 
for minimizing metabolic activation of new drug candi-
dates in drug discovery. Handb Exp Pharmacol 2010; 
196:511-44.
126. Kemp DC, Fan PW, Stevens JC. Characterization of 
raloxifene glucuronidation in vitro: contribution of 
intestinal metabolism to presystemic clearance. Drug 
Metab Dispos 2002; 30:694-700.